We therefore investigated whether this combination could be effective in treating MYC-driven p53 wild type and null lymphoma in vivo. In mice transplanted with Tp53−/− Eμ-Myc B-lymphoma cells, CX-5461 and CHK1/2i as single agents provided a modest survival benefit (median 3.5 days) and no survival benefit, respectively (Figure 5D). This evidence concerns the gene CHEK1 and lymphoma.